RxSight, Inc. Common Stock earnings per share and revenue
On 05 de nov. de 2025, RXST reported earnings of -0.24 USD per share (EPS) for Q3 25, beating the estimate of -0.38 USD, resulting in a 37.87% surprise. Revenue reached 30.34 milhão, compared to an expected 25.78 milhão, with a 17.67% difference. The market reacted with a +3.24% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analistas forecast an EPS of -0.34 USD, with revenue projected to reach 28.08 milhão USD, implying an aumentar of 41.67% EPS, and diminuir of -7.44% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AngioDynamics, Inc.
Report Date
06 de jan. de 2026 Para Q2 26
Estimativa
-$0.10
Real
$0.00
Surpresa
+100.00%
FAQ
What were RxSight, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, RxSight, Inc. Common Stock reported EPS of -$0.24, beating estimates by 37.87%, and revenue of $30.34M, 17.67% above expectations.
How did the market react to RxSight, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 3.24%, changed from $8.34 before the earnings release to $8.61 the day after.
When is RxSight, Inc. Common Stock expected to report next?
The next earning report is scheduled for 26 de fev. de 2026.
What are the forecasts for RxSight, Inc. Common Stock's next earnings report?
Based on 13
analistas, RxSight, Inc. Common Stock is expected to report EPS of -$0.34 and revenue of $28.08M for Q4 2025.